Short Communication - Journal of Plant Biotechnology and Microbiology (2023) Volume 6, Issue 3
Synthetic Biology for Plant-Based Pharmaceutical Production
John Smith*Department of Plant sciences and Technology, The University of Utah, Salt Lake City, UT 84112, United States
- *Corresponding Author:
- John Smith
Department of Plant sciences and Technology
The University of Utah, Salt Lake City
UT 84112, United States
E-mail: johnsmith.js@utah.edu
Received: 08-May-2023, Manuscript No. AAPBM-23-101163; Editor assigned: 09-May-2023, PreQC No.AAPBM-23-101163(PQ); Reviewed: 23-May-2023, QC No.AAPBM-23-101163; Revised: 25-May-2023, Manuscript No. AAPBM-23-101163(R); Published: 07-June-2023, DOI: 10.35841/aapbm-6.3.147
Citation: Smith J. Synthetic biology for plant-based pharmaceutical production. J Plant Bio Technol.2023;6(3):147
Introduction
Synthetic biology, a multidisciplinary field that combines biology, engineering, and computational sciences, has emerged as a powerful tool for advancing plant-based pharmaceutical production. Traditional methods of pharmaceutical production often rely on chemical synthesis or microbial fermentation, which can be costly, time-consuming, and environmentally demanding. However, through synthetic biology approaches, plants can be engineered to produce valuable pharmaceutical compounds efficiently, sustainably, and at a lower cost. This article explores the applications and benefits of synthetic biology in plant-based pharmaceutical production [1].
Synthetic biology offers a toolkit of genetic engineering techniques that enable precise manipulation of plant genomes. Using these tools, scientists can introduce or modify genes to optimize plant metabolism for pharmaceutical compound production. The toolkit includes methods such as gene synthesis, genome editing (e.g., CRISPR/Cas9), promoter engineering, and pathway engineering. These tools allow the introduction or enhancement of biosynthetic pathways, gene expression regulation, and metabolic engineering in plants [2].
Metabolic engineering plays a crucial role in the design and optimization of plant-based pharmaceutical production. Synthetic biology allows the alteration of plant metabolic pathways to enhance the production of desired compounds. By introducing genes encoding specific enzymes or modifying existing enzymes, researchers can redirect metabolic flux towards the production of pharmaceutical precursors or final compounds. Additionally, synthetic biology enables the engineering of plant tissues or organelles to enhance yield, facilitate compound extraction, or improve bioavailability.
Plant-based pharmaceutical production offers several advantages over traditional methods. Firstly, plants serve as cost-effective bioreactors, as they can be cultivated on a large scale and do not require costly infrastructure. Moreover, plants are amenable to scalable cultivation practices, making them suitable for both small-scale and industrial production. Additionally, plant-based systems offer the potential for rapid scalability and flexibility, allowing for the production of a wide range of pharmaceutical compounds. Furthermore, plant-derived pharmaceuticals often possess greater safety and stability compared to their synthetic counterparts [3].
Examples of Successful Plant-Based Pharmaceutical Production: Several successful examples demonstrate the potential of synthetic biology in plant-based pharmaceutical production. One prominent example is the production of artemisinin, a potent antimalarial compound, in engineered tobacco plants. Through metabolic engineering, researchers increased the production of artemisinin precursors in the plant, leading to a more cost-effective and sustainable source of this vital drug. Another example is the production of recombinant proteins, such as vaccines and antibodies, in plant-based systems. Plant-produced vaccines have shown promising results, with increased scalability and potential for rapid response during disease outbreaks [4].
Challenges and Future Perspectives: While synthetic biology offers exciting opportunities for plant-based pharmaceutical production, several challenges need to be addressed. One challenge is the optimization of production yields, as plants often exhibit low levels of pharmaceutical compound accumulation. Efforts are underway to further enhance metabolic flux, enzyme efficiency, and compound extraction methods. Additionally, regulatory frameworks and public acceptance need to be considered, ensuring safety, quality control, and proper labeling of plant-derived pharmaceuticals [5].
Conclusion
Synthetic biology is revolutionizing plant-based pharmaceutical production by offering efficient and sustainable approaches for the synthesis of valuable compounds. The combination of genetic engineering, metabolic engineering, and synthetic biology tools enables the design and optimization of plant systems for the production of pharmaceuticals with numerous advantages over traditional methods. With ongoing advancements and collaborative efforts, plant-based pharmaceutical production has the potential to offer affordable and accessible treatments, contributing to global health and well-being.
References
- Vernikos J, Walter N, Worms JC, et al. THESEUS: The European research priorities for human exploration of space. Npj Microgravity. 2016;2(1):1-3.
- Fu Y, Li L, Xie B, Dong C, et al. How to establish a Bioregenerative Life Support System for long-term crewed missions to the Moon or Mars. Astrobiology. 2016;16(12):925-36.
- Rothschild LJ. Synthetic biology meets bioprinting: enabling technologies for humans on Mars (and Earth). Biochem Soc Trans. 2016;44(4):1158-64.
- Kiss JZ. Plant biology in reduced gravity on the M oon and M ars. plant Biol. 2014;16:12-7.
- Dutta PK, Lin S, Loskutov A, et al. Reengineering the optical absorption cross-section of photosynthetic reaction centers. J Am Chem Soc. 2014;136(12):4599-604.
Indexed at, Google scholar, Cross Ref
Indexed at, Google scholar, Cross Ref
Indexed at, Google scholar, Cross Ref
Indexed at, Google scholar, Cross Ref